Microbix Presenting at Muskoka Capital Conference

By Pavel Zhelev | September 21, 2022

Microbix Reports Results for Q3 Fiscal 2022

By Pavel Zhelev | August 11, 2022

Microbix Executes Substantial QAPs Supply Agreement

By Pavel Zhelev | August 10, 2022

Microbix Presenting STI Multiplex Test Controls at AACC

By Pavel Zhelev | July 26, 2022

Microbix Presenting Test Validation Methods at AACC

By Pavel Zhelev | June 3, 2022 Microbix Antigen-test QAPs Now Available For Clinical Use

Microbix Reports Record Results for Q2 Fiscal 2022

By Pavel Zhelev | May 12, 2022

Microbix Presenting Omicron Test Control Results at CVS

By Pavel Zhelev | April 29, 2022

Microbix Presenting at the 2022 Bloom Burton Conference

By Pavel Zhelev | April 28, 2022

AGM PRESENTATION 2022

By Pavel Zhelev | April 19, 2022

Microbix Presenting Respiratory Virus Controls Data at Two Events

By Pavel Zhelev | April 19, 2022

Microbix Presenting HPV Product Results at EUROGIN

By Pavel Zhelev | April 8, 2022

Microbix Announces Annual and Special Meeting Voting Results

By Pavel Zhelev | March 31, 2022

Microbix Invests to Further Scale Its Business

By Pavel Zhelev | March 29, 2022 Microbix Announces Quality Products Distribution Agreement

Virtual AGM on March 30, 2022

By Pavel Zhelev | March 8, 2022

Microbix Announces Issuance of Stock Options

By Pavel Zhelev | February 24, 2022

Microbix Announces Nomination to Board of Directors

By Pavel Zhelev | February 22, 2022

Microbix Presenting at Capital Conference in B.C.

By Pavel Zhelev | February 17, 2022

Microbix Advances Commissioning of Sites Two and Three

By Pavel Zhelev | February 15, 2022

Microbix Reports Record Results for Q1 Fiscal 2022

By Pavel Zhelev | February 10, 2022

Microbix Launches Omicron Variant Test Control

By Pavel Zhelev | February 1, 2022

Microbix Receives $4.7 Million Order for Viral Transport Medium

By Pavel Zhelev | December 24, 2021

Microbix Reports Record Results for Fiscal 2021

By Pavel Zhelev | December 23, 2021

Microbix Launches Multiplex Respiratory PCR-Test Control

By Pavel Zhelev | December 20, 2021

Microbix Expands Pandemic Test Controls (QAPs™) Portfolio

By Pavel Zhelev | November 17, 2021

Microbix Receives $2.7 Million from Exercise of Warrants

By Pavel Zhelev | October 27, 2021

Microbix Poster Covering SARS-CoV-2 Variants of Concern (VOC) QAPs at AACC 2021

By Pavel Zhelev | October 6, 2021

Microbix Makes Early Repayment of 9% Interest Debenture

By Pavel Zhelev | October 4, 2021 Microbix Announces Quality Products Distribution Agreement

Microbix Presenting Product Results at AACC

By Pavel Zhelev | September 27, 2021

Microbix Presenting at Muskoka Capital Conference

By Pavel Zhelev | September 23, 2021

Microbix Reports Record Results for Q3 Fiscal 2021

By Pavel Zhelev | August 12, 2021

Microbix Upgrades U.S. OTC Market & Investor Relations

By Pavel Zhelev | August 3, 2021

Microbix Posters at 31st ECCMID 2021

By Pavel Zhelev | July 16, 2021

Microbix Presenting Product Results to Industry

By Pavel Zhelev | July 8, 2021

Microbix Announces Quality Products Distribution Agreement

By Pavel Zhelev | July 7, 2021 Microbix Announces Quality Products Distribution Agreement

Microbix Secures Third Ontario Manufacturing Site

By Pavel Zhelev | June 3, 2021

Microbix Announces Quality Products Distribution Agreement

By Pavel Zhelev | May 31, 2021 Microbix Announces Quality Products Distribution Agreement

Microbix Announces Closing of Offering and Private Placement

By Pavel Zhelev | May 19, 2021

Microbix Reports Record Results for Q2 Fiscal 2021

By Pavel Zhelev | May 13, 2021 Record Q2 Sales of $4.35 million, Record Net Earnings of $0.8 million

Microbix Announces $6.0 Million of Financings

By Pavel Zhelev | April 28, 2021

Microbix & SpeeDx Form Exclusive Collaboration

By Pavel Zhelev | April 26, 2021 Microbix & SpeeDx Form Exclusive Collaboration

Microbix Receives $4.25 Million Order For Viral Transport Medium

By Pavel Zhelev | April 23, 2021 Microbix Receives $4.25 Million Order For Viral Transport Medium

Microbix to Present at Bloom Burton Investor Conference

By Pavel Zhelev | April 19, 2021 Microbix to Present at Bloom Burton Investor Conference

Microbix Announces Annual and Special Meeting Voting Results

By Pavel Zhelev | March 31, 2021 Microbix Announces Annual and Special Meeting Voting Results

Virtual AGM on March 30, 2021

By Pavel Zhelev | March 30, 2021 Virtual AGM on March 30, 2021

AGM Presentation – March 2022

By Pavel Zhelev | March 29, 2021 Microbix

Microbix & Seegene Canada Form COVID-Variant Collaboration

By Pavel Zhelev | March 15, 2021 Microbix & Seegene Canada Form COVID-Variant Collaboration

Microbix Antigen-test QAPs Now Available For Clinical Use

By Pavel Zhelev | March 11, 2021 Microbix Antigen-test QAPs Now Available For Clinical Use

Microbix Announces Issuance of Stock Options

By Pavel Zhelev | February 18, 2021 Record Q2 Sales of $4.35 million, Record Net Earnings of $0.8 million

Microbix Announces Quality Products Distribution Agreement

By Pavel Zhelev | February 16, 2021 Microbix Announces Quality Products Distribution Agreement

Microbix Reports Results for Q1 Fiscal 2021

By Pavel Zhelev | February 11, 2021

Microbix Announces Material First Sales of Viral Transport Medium

By Pavel Zhelev | February 9, 2021

Microbix Viral Transport Medium Now Available

By Pavel Zhelev | January 28, 2021 Microbix Receives $4.25 Million Order For Viral Transport Medium

Microbix & Copan Italia Execute Strategic Agreement

By Pavel Zhelev | December 21, 2020 Microbix Presenting COVID-19 Product Results To Industry

Microbix Reports Results for Fiscal 2020

By Pavel Zhelev | December 18, 2020

Microbix Presenting Product Results at AACC

By Pavel Zhelev | December 15, 2020 Microbix & SpeeDx Form Exclusive Collaboration

Microbix Announces Addition to Board of Directors

By Pavel Zhelev | December 7, 2020 Microbix Announces Addition to Board of Directors